{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:44:00Z","timestamp":1786592640450,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioPsychoSocial Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs) to chronic myeloid leukemia (CML) therapy has revolutionized the treatment of this disease. Although regular TKI intake is a prerequisite for successful therapy, it has been shown that a significant proportion of patients are non-compliant. Recently there is growing evidence that personality traits may influenced the tendency for non-adherence to treatment in patients with chronic diseases. As far as we know, such a relationship in patients with CML has not been examined, yet. The aim of our study was to determine if personality traits favor non-adherence to treatment recommendations. We investigated the relationship between five-factor model personality factors (conscientiousness, neuroticism, agreeableness, extraversion, and openness) and medication non-adherence. We also checked if the patients with type A and type D personality, were at higher risk of poor medication adherence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The following tools were used: self-constructed survey, the NEO-Five Factor Inventory, the Framingham Type A Scale, the D-Scale 14. The study included 140 CML patients treated with imatinib, dasatinib, or nilotinib.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>39% of patients reported skipping at least one dose of medication in the month prior to follow-up visit. 51% admitted to skipping such doses from the start of their treatment to the time at which our assessment was performed. We did not find any relationship between the mean values of the analyzed factors of the Big Five (neuroticism, extraversion, openness, agreeableness, conscientiousness) and adherence. However, our analysis revealed that CML patients who admitted to missing doses of drugs during the entire course of treatment demonstrated greater intensity of type A personality traits (<jats:italic>p<\/jats:italic>\u2009=\u20090.020). Regarding both factors of type D personality, it was revealed that higher level of negative affectivity significantly decreased the adherence (<jats:italic>p<\/jats:italic>\u2009=\u20090.020).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results of our study indicate that screening for type D and A personalities may help to identify patients who are at higher risk of poor medication adherence.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13030-023-00261-w","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T21:03:27Z","timestamp":1674162207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-1483","authenticated-orcid":false,"given":"Anna","family":"Rychter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Miniszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"G\u00f3ra-Tybor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"261_CR1","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, de Bock R, Verhoef G, Zach\u00e9e P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401\u201311. https:\/\/doi.org\/10.1182\/blood-2008-12-196543.","journal-title":"Blood"},{"key":"261_CR2","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1200\/JCO.2008.19.2419","volume":"27","author":"G Kimmick","year":"2009","unstructured":"Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009;27:3445\u201351. https:\/\/doi.org\/10.1200\/JCO.2008.19.2419.","journal-title":"J Clin Oncol"},{"key":"261_CR3","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"A Ibrahim","year":"2011","unstructured":"Ibrahim A, Eliasson L, Apperley J, Milojkovic D, Bua M, Szydlo R, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy. Blood. 2011;117:3733\u20136. https:\/\/doi.org\/10.1182\/blood-2010-10-309807.","journal-title":"Blood"},{"key":"261_CR4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/bjc.2012.348","volume":"107","author":"F Efficace","year":"2012","unstructured":"Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107:904\u20139. https:\/\/doi.org\/10.1038\/bjc.2012.348.","journal-title":"Br J Cancer"},{"key":"261_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/ajh.23180","volume":"87","author":"E Jabbour","year":"2012","unstructured":"Jabbour E, Kantarjian H, Eliasson L, Cornelison M, Marinet D. Patent adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012;87:687\u201391. https:\/\/doi.org\/10.1002\/ajh.23180.","journal-title":"Am J Hematol"},{"key":"261_CR6","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1097\/00004872-200409000-00029","volume":"22","author":"B van Wijk","year":"2004","unstructured":"van Wijk B, Klungel O, Heerdink E, de Boer A. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens. 2004;22:1831\u20137. https:\/\/doi.org\/10.1097\/00004872-200409000-00029.","journal-title":"J Hypertens"},{"key":"261_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12032-017-0958-6","volume":"34","author":"A Rychter","year":"2017","unstructured":"Rychter A, Jerzmanowski P, Ho\u0142ub A, Specht-Szwoch Z, Kalinowska V, T\u0119gowska U, et al. Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors. Med Oncol. 2017;34:104. https:\/\/doi.org\/10.1007\/s12032-017-0958-6.","journal-title":"Med Oncol"},{"key":"261_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10865-010-9247-y","volume":"33","author":"JM Bruce","year":"2010","unstructured":"Bruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med. 2010;33:219\u201327. https:\/\/doi.org\/10.1007\/s10865-010-9247-y.","journal-title":"J Behav Med"},{"key":"261_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/2327-6924.12069","volume":"26","author":"M Axelsson","year":"2014","unstructured":"Axelsson M, Brink E, L\u00f6tvall J. A personality and gender perspective on adherence and health-related quality of life in people with asthma and\/or allergic rhinitis. J Am Assoc Nurse Pract. 2014;26:32\u20139. https:\/\/doi.org\/10.1002\/2327-6924.12069.","journal-title":"J Am Assoc Nurse Pract"},{"key":"261_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1348\/135910710X524219","volume":"16","author":"A Jerant","year":"2011","unstructured":"Jerant A, Chapman B, Duberstein P, Robbins J, Franks P. Personality and medication non-adherence among older adults enrolled in a six-year trial. Br J Health Psychol. 2011;16:151\u201369. https:\/\/doi.org\/10.1348\/135910710X524219.","journal-title":"Br J Health Psychol"},{"key":"261_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/dme.12339","volume":"31","author":"TC Skinner","year":"2014","unstructured":"Skinner TC, Bruce DG, Davis TME, Davis WA. Research: educational and psychological issues personality traits, self-care behaviours and glycaemic control in type 2 diabetes: the Fremantle Diabetes Study Phase II. Diabet Med. 2014;31:487\u201392. https:\/\/doi.org\/10.1111\/dme.12339.","journal-title":"Diabet Med"},{"key":"261_CR12","volume-title":"Type A behaviour and your heart","author":"M Friedman","year":"1974","unstructured":"Friedman M, Rosenman RH. Type A behaviour and your heart. New York: Knopf; 1974."},{"key":"261_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/9780470713860.ch10","volume-title":"Handbook of personality and health","author":"S Torgersen","year":"2006","unstructured":"Torgersen S, Vollrath M. Personality types, personality traits and risky health, behaviours. In: Vollrath ME, editor. Handbook of personality and health. Chichester: Wiley; 2006. p. 215\u201333."},{"key":"261_CR14","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.1959.03000290012005","volume":"169","author":"M Friedman","year":"1959","unstructured":"Friedman M, Rosenman RH. Association of specific overt behavior pattern with blond and cardiovascular findings. JAMA. 1959;169:1286\u201396.","journal-title":"JAMA"},{"key":"261_CR15","volume-title":"Styl \u017cycia a zdrowie.\u00a0Wz\u00f3r zachowania A","author":"K Wrze\u015bniewski","year":"1993","unstructured":"Wrze\u015bniewski K. Styl \u017cycia a zdrowie.\u00a0Wz\u00f3r zachowania A. Warszawa: PAN; 1993."},{"key":"261_CR16","first-page":"313","volume":"34","author":"T Zaleska","year":"1992","unstructured":"Zaleska T, Tylka J. Typ a zachowania a choroba niedokrwienna serca. Kard Pol. 1992;34:313\u20138.","journal-title":"Kard Pol"},{"key":"261_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/pon.2960010105","volume":"1","author":"DR Ragland","year":"1992","unstructured":"Ragland DR, Brand RJ, Fox BH. Type A\/B behavior and cancer mortality: the confounding\/mediating effect of covariates. Psychooncology. 1992;1:25\u201333. https:\/\/doi.org\/10.1002\/pon.2960010105.","journal-title":"Psychooncology"},{"issue":"6","key":"261_CR18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.diabet.2018.11.005","volume":"45","author":"J-C Chauvet-G\u00e9linier","year":"2019","unstructured":"Chauvet-G\u00e9linier J-C, Mosca-Boidron A-L, Lemogne C, et al. Type a competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes. Diabetes Metab. 2019;45(6):582\u20135. https:\/\/doi.org\/10.1016\/j.diabet.2018.11.005.","journal-title":"Diabetes Metab"},{"key":"261_CR19","unstructured":"Marcinkowska-Bachli\u0144ska M, Ma\u0142ecka-Panas E. The role of the type A behaviour in the pathogenesis of gastroesophageal reflux disease. Przegl Gastroenterol. 2006;1:2: 98\u2013104."},{"key":"261_CR20","unstructured":"Chesney MA, Hecker MH, Black GW. Coronary-prone competents of type A behavior in the WCGS: a new methology. Houston BK, Snyder CR (editor). Type A behavior pattern: research, theory and interwention. New York: Wiley;\u00a01988. p. 26\u201335."},{"key":"261_CR21","first-page":"121","volume":"2","author":"M Friedman","year":"1984","unstructured":"Friedman M, Powell LH. The diagnosis and quantitative assessment of type A behavior: introduction and description of the videotyped structured interview. Integr Psychiatry. 1984;2:121\u20139.","journal-title":"Integr Psychiatry"},{"key":"261_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1037\/\/0278-6133.10.1.18","volume":"10","author":"JC Barefoot","year":"1991","unstructured":"Barefoot JC, Peterson BL, Dahlstrom WG. Hostility patterns and health implications: correlates of Cook-Medley hostility scale scores in a national survey. Health Psychol. 1991;10:18\u201324. https:\/\/doi.org\/10.1037\/\/0278-6133.10.1.18.","journal-title":"Health Psychol"},{"key":"261_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1365-2869.2007.00620.x","volume":"16","author":"A Brostr\u00f6m","year":"2007","unstructured":"Brostr\u00f6m A, Str\u00f6mberg A, Martensson J, Ulander M, Harder L, Svanborg E. Association of type D personality to perceived side effects and adherence in CPAP-treated patients with OSAS. J Sleep Res. 2007;16:439\u201347. https:\/\/doi.org\/10.1111\/j.1365-2869.2007.00620.x.","journal-title":"J Sleep Res"},{"key":"261_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.hrtlng.2015.03.006","volume":"44","author":"JR Wu","year":"2015","unstructured":"Wu JR, Song EK, Moser DK, Type D. Personality, self-efficacy, and medication adherence in patients with heart failure-A mediation analysis. Heart Lung. 2015;44:276\u201381. https:\/\/doi.org\/10.1016\/j.hrtlng.2015.03.006.","journal-title":"Heart Lung"},{"key":"261_CR25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/08870446.2010.488265","volume":"26","author":"L Williams","year":"2011","unstructured":"Williams L, O\u2019Connorb RC, Grubbc N, O\u2019Carroll R. Type D personality predicts poor medication adherence in myocardial infarction patients. Psychol Health. 2011;26:703\u201312. https:\/\/doi.org\/10.1080\/08870446.2010.488265.","journal-title":"Psychol Health"},{"key":"261_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jpsychores.2016.09.003","volume":"90","author":"J Crawshaw","year":"2016","unstructured":"Crawshaw J, Auyeung V, Norton S, Weinman J. Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: a systematic review and meta-analysis. J Psychosom Res. 2016;90:10\u201332. https:\/\/doi.org\/10.1016\/j.jpsychores.2016.09.003.","journal-title":"J Psychosom Res"},{"key":"261_CR27","volume-title":"Revised NEO personality inventory manual","author":"PT Costa","year":"1992","unstructured":"Costa PT, McCrae RR Jr. Revised NEO personality inventory manual. Odessa: Psychological Assessment Resources, Inc; 1992."},{"key":"261_CR28","volume-title":"Inwentarz osobowo\u015bci NEO-FFI Costy i McCrae","author":"B Zawadzki","year":"1998","unstructured":"Zawadzki B, Strelau J, Szczepaniak P, \u015aliwi\u0144ska M. Inwentarz osobowo\u015bci NEO-FFI Costy i McCrae. Warszawa: Pracownia Test\u00f3w Psychologicznych PTP; 1998."},{"key":"261_CR29","unstructured":"Framingham. Heart Study - www.framinghamheartstudy.org."},{"key":"261_CR30","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2105\/ajph.49.10.1349","volume":"49","author":"TR Dawber","year":"1959","unstructured":"Dawber TR, Kannel WB, Revotskie N, Stokes JI, Kagan A, Gordon T. Some factors associated with the development of coronary heart disease. Six years\u2019 follow-up experience in the Framingham study. Am J Public Health. 1959;49:1349\u201356. https:\/\/doi.org\/10.2105\/ajph.49.10.1349.","journal-title":"Am J Public Health"},{"key":"261_CR31","volume-title":"Narz\u0119dzia pomiaru w promocji i psychologii zdrowia","author":"Z Juczy\u0144ski","year":"2001","unstructured":"Juczy\u0144ski Z. Narz\u0119dzia pomiaru w promocji i psychologii zdrowia. Warszawa: Pracownia Test\u00f3w Psychologicznych Polskiego Towarzystwa Psychologicznego; 2001."},{"key":"261_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.psy.0000149256.81953.49","volume":"67","author":"J Denollet","year":"2005","unstructured":"Denollet J. DS14: standard assessment of negative affectivity, social inhibition and type D personality. Psych Med. 2005;67:89\u201397. https:\/\/doi.org\/10.1097\/01.psy.0000149256.81953.49.","journal-title":"Psych Med"},{"key":"261_CR33","volume-title":"Narz\u0119dzia pomiaru stresu i radzenia sobie ze stresem","author":"Z Juczy\u0144ski","year":"2009","unstructured":"Juczy\u0144ski Z, Ogi\u0144ska-Bulik N. Narz\u0119dzia pomiaru stresu i radzenia sobie ze stresem. Warszawa: Pracownia Test\u00f3w Psychologicznych PTP; 2009."},{"key":"261_CR34","first-page":"409","volume":"28","author":"D Mili\u010di\u0107","year":"2016","unstructured":"Mili\u010di\u0107 D, Brajkovi\u0107 L, Ma\u010dek JL, Andri\u0107 A, Ardali\u0107 \u017d, Buratovi\u0107 T, et al. Type a personality, stress, anxiety and health locus of control in patients with acute myocardial infarction. Psychiatr Danub. 2016;28:409\u201314.","journal-title":"Psychiatr Danub"},{"key":"261_CR35","doi-asserted-by":"publisher","first-page":"e0146892","DOI":"10.1371\/journal.pone.0146892","volume":"11","author":"X Li","year":"2016","unstructured":"Li X, Zhang S, Xu H, Tang X, Zhou H, Yuan J, et al. Type D personality predicts poor medication adherence in Chinese patients with type 2 diabetes mellitus: a six-month follow-up study. PLoS One. 2016;11:e0146892. https:\/\/doi.org\/10.1371\/journal.pone.0146892.","journal-title":"PLoS One"},{"key":"261_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/08870440290025858","volume":"5","author":"F De Fruyt","year":"2002","unstructured":"De Fruyt F, Denollet J. Type D personality: a five factor model perspective. Psych Health. 2002;5:671\u201383. https:\/\/doi.org\/10.1080\/08870440290025858.","journal-title":"Psych Health"},{"key":"261_CR37","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/JCP.0000000000000541","volume":"36","author":"H Wouters","year":"2016","unstructured":"Wouters H, Amin D, Taxis K, Heerdink ER, Egberts A, Gardarsdottir H. Associations between personality traits and adherence to antidepressants assessed through self-report, electronic monitoring, and pharmacy dispensing data: a pilot study. J Clin Psychopharmacol. 2016;36:465\u201371. https:\/\/doi.org\/10.1097\/JCP.0000000000000541.","journal-title":"J Clin Psychopharmacol"},{"key":"261_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/070674370404900205","volume":"49","author":"NL Cohen","year":"2004","unstructured":"Cohen NL, Ross EC, Bagby RM, Farvolden P, Kennedy SH. The 5-factor model of personality and antidepressant medication compliance. Can J Psychiatry. 2004;49:106\u201313. https:\/\/doi.org\/10.1177\/070674370404900205.","journal-title":"Can J Psychiatry"},{"key":"261_CR39","doi-asserted-by":"publisher","first-page":"e18241","DOI":"10.1371\/journal.pone.001824","volume":"6","author":"M Axelsson","year":"2011","unstructured":"Axelsson M, Brink E, Lundgren J, L\u00f6tvall J. The influence of personality traits on reported adherence to medication in individuals with chronic disease: an epidemiological study in West Sweden. PLoS One. 2011;6:e18241. https:\/\/doi.org\/10.1371\/journal.pone.001824.","journal-title":"PLoS One"},{"key":"261_CR40","doi-asserted-by":"publisher","first-page":"e0278534","DOI":"10.1371\/journal.pone.0278534","volume":"17","author":"T Adachi","year":"2022","unstructured":"Adachi T, Tsunekawa Y, Tanimura D. Association between the big five personality traits and medication adherence in patients with cardiovascular disease: a cross-sectional study. PLoS One. 2022;17:e0278534. https:\/\/doi.org\/10.1371\/journal.pone.0278534.","journal-title":"PLoS One"},{"key":"261_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/jpm10030126","volume":"10","author":"BG Toelle","year":"2020","unstructured":"Toelle BG, Marks GB, Dunn SM. Psychological andmedical characteristics associated with non-adherence to prescribed dailyinhaled corticosteroid. J Pers Med. 2020;10:126. https:\/\/doi.org\/10.3390\/jpm10030126.","journal-title":"J Pers Med"},{"key":"261_CR42","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1037\/0033-2909.116.3.429","volume":"116","author":"A Feingold","year":"1994","unstructured":"Feingold A. Gender differences in personality - a meta-analysis. Psychol Bull. 1994;116:429\u201356. https:\/\/doi.org\/10.1037\/0033-2909.116.3.429.","journal-title":"Psychol Bull"}],"container-title":["BioPsychoSocial Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13030-023-00261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13030-023-00261-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13030-023-00261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T12:23:00Z","timestamp":1674822180000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpsmedicine.biomedcentral.com\/articles\/10.1186\/s13030-023-00261-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["261"],"URL":"https:\/\/doi.org\/10.1186\/s13030-023-00261-w","relation":{},"ISSN":["1751-0759"],"issn-type":[{"value":"1751-0759","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"12 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local ethics committee; the Bioethics Committee of the Medical University of Lodz (No. RNN\/226\/15\/KE); and has been approved by the appropriate institutional and\/or national research ethics committee. It was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval\u00a0and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author JGT has received speaker and consultancy honorariums from Novartis, BMS, Incyte, and Pfizer. The remaining authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}